Veradermics, Incorporated (NYSE:MANE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Posted by on Aug 2nd, 2026

Shares of Veradermics, Incorporated (NYSE:MANE – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the nine analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $153.00.

A number of brokerages have issued reports on MANE. Lifesci Capital initiated coverage on shares of Veradermics in a report on Tuesday, June 16th. They issued an “outperform” rating and a $135.00 target price on the stock. Jefferies Financial Group upped their target price on Veradermics from $138.00 to $182.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings initiated coverage on Veradermics in a research report on Tuesday, May 26th. They set a “sell (d+)” rating on the stock. B. Riley Financial started coverage on Veradermics in a research report on Wednesday, July 15th. They set a “buy” rating and a $170.00 price objective for the company. Finally, UBS Group set a $170.00 price objective on Veradermics in a research note on Wednesday, July 15th.

View Our Latest Analysis on Veradermics

Veradermics Stock Performance

Veradermics stock opened at $105.05 on Friday. The business has a 50-day simple moving average of $108.02. Veradermics has a 1 year low of $32.00 and a 1 year high of $131.24. The company has a market cap of $4.39 billion and a P/E ratio of -79.58.

Veradermics (NYSE:MANE – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.76).

About Veradermics

(Get Free Report)

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.

Featured Stories

Analyst Recommendations for Veradermics (NYSE:MANE)

Receive News & Ratings for Veradermics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradermics and related companies with MarketBeat.com's FREE daily email newsletter.